CSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes
Status:
Not yet recruiting
Trial end date:
2027-12-31
Target enrollment:
Participant gender:
Summary
The investigators aim to determine, using a point-of-care randomized controlled trial design,
if hemodialysis patients, who are randomized to metoprolol succinate (a dialyzable, beta-1
selective beta blocker), have an improved cardiovascular outcome compared to those randomized
to carvedilol (a non-dialyzable, non-selective beta blocker with alpha-1 antagonist
properties). The investigators will also examine intervention practices to identify
components that best support engagement and sustainability.